Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
Background: Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, are administered intravitreally for the treatment of wet or exudative age-related macular degeneration (ARMD). Systemic use of bevacizumab has been linked to a wide range of renal adverse effe...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Society of Diabetic Nephropathy Prevention,
2017-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |